BRAF mutant tumours are associated with poorer prognosis [28]; in particular, the BRAFV600E mutation is associated with a lack of response to anti-EGFR therapies (such as cetuximab) if not treated simultaneously with an anti-BRAFV600E treatment (such as encorafenib) [30]. Here, BRAF is linked to neoplasm.